Munich - Delayed Quote EUR

Viking Therapeutics Inc (1VT.MU)

22.46

+0.09

+(0.42%)

As of 8:08:07 AM GMT+2. Market Open.

Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ...

Viking Therapeutics Inc (VKTX) reports significant progress in clinical trials and maintains a strong cash position despite increased R&D and administrative costs.

GuruFocus.com 1 hour ago

VKTX
Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying

We recently published a list of 20 Takeover Rumors Hedge Funds Are Buying. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other takeover rumor stocks hedge funds are buying. Hedge funds tend to pile up on a stock that gains or is expected to gain […]

Insider Monkey 8 hours ago

VKTX
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks yesterday

VKTX
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Eli Lilly's stock surges as its investigational oral GLP-1 pill, orforglipron, achieves the primary and key secondary goals in the first late-stage study for adults with T2D.

Zacks 2 days ago

LLY

VKTX

NVO
Viking Therapeutics to Report Q1 Earnings: What's in the Cards?

Devoid of marketed drugs, investors will focus on VKTX's pipeline updates when it reports first-quarter earnings.

Zacks 2 days ago

VKTX
Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735

Viking Therapeutics (NasdaqCM:VKTX) saw its stock rise by 11% over the last week, coinciding with significant developments in its clinical trials. The company's completion of subject enrollment for the Phase 2 clinical trial of VK2735, targeting weight loss, and promising results from earlier phases have bolstered investor confidence, contributing to the stock's positive movement. The recent announcements about both oral and subcutaneous formulations underscore the potential of VK2735. With...

Simply Wall St. 5 days ago

VKTX
H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

H.C. Wainwright says the bar is set for oral GLP-1s following this morning’s type 2 diabetes data from Eli Lilly (LLY). The firm continues to expect Viking Therapeutics (VKTX) to “differentiate” with its dual GLP-1/GIP asset VK2735. The data collected in the Phase 1 assessing oral VK2735 is at 28 days exhibited up to an 8.2% reduction in body weight was observed, and oral VK2735 maintained excellent tolerability profile through 100 mg dose level with 99% of adverse events being mild to moderate,

TipRanks 5 days ago

LLY

VKTX
Eli Lilly jumps as results from weight-loss pill study rival competitor’s

Shares of Eli Lilly (LLY) jumped on Thursday morning after the company announced topline Phase 3 results from ACHIEVE-1, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone. Commenting on the news, Leerink said that the once-daily oral GLP-1 pill showed similar efficacy and safety relative to weekly injectable semaglutide, made by Novo Nordisk (NVO). PRIMARY ENDPOINT MET: Eli Lilly anno

TipRanks 5 days ago

LLY

NONOF

NVO
JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

JPMorgan analyst Hardik Parikh says Eli Lilly’s (LLY) Phase 3 data for orforglipron in type 2 diabetes suggest a “highly competitive profile” for the drug. The firm views the data as its base case scenario, whereby Structure Therapeutics (GPCR) shares could be up double-digit percent in this scenario on a “highly favorable read-through” and Viking Therapeutics (VKTX) could move mid-single-digit in either direction. JPMorgan’s focus was primarily on orfoglipron’s tolerability profile with the ext

TipRanks 5 days ago

GPCR

LLY

VKTX
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $23.94, representing a +1.44% change from its previous close.

Zacks 6 days ago

VKTX

^GSPC
Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Eli Lilly stock jetted higher Thursday after the company said its diabetes and weight-loss pill helped patients lose up to 16 pounds.

Investor's Business Daily 6 days ago

VKTX

LLY

NONOF
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.

Motley Fool 6 days ago

LLY

NVO

VKTX
2 Stocks Down by 25% or More This Year to Buy and Hold

Equity markets have had a rough go of it this year due to President Trump's macroeconomic policies. To that end, let's consider two stocks that have declined by at least 25% this year and look attractive: Viking Therapeutics (NASDAQ: VKTX) and PayPal (NASDAQ: PYPL). Drugmakers without a single therapy on the market tend to be somewhat risky, but investing in these companies early enough can lead to life-changing returns.

Motley Fool 6 days ago

PYPL

VKTX
Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2025 after the market close on Wednesday, April 23, 2025.

PR Newswire 7 days ago

VKTX
Pfizer Halts Obesity Pill Development Amid Safety Concerns

PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.

Zacks 8 days ago

PFE

LLY

NVO
Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts “limited reaction” in Pfizer’s shares following the news, JPMorgan tells investors that the decision is “mostly a positive” for Structure and Viking, both developing drugs in the

TipRanks 8 days ago

NONOF

NVO

LLY
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (NASDAQ: VKTX), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off. Progress toward regulatory approval with multiple data readouts expected later this year could be the catalyst for shares to rebound sharply.

Motley Fool 8 days ago

VKTX
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.

Zacks 8 days ago

PFE

NVO

VKTX
Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look at where Viking Therapeutics, Inc. (NASDAQ:VKTX) stands against other biotech stocks that dominate Monday’s top gainers. The stock market kicked off the shortened trading week on a positive note, with Wall Street’s major […]

Insider Monkey 9 days ago

VKTX

PFE
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

Motley Fool 9 days ago

NVO

VKTX

LLY

Performance Overview

Return	1VT.MU	S&P 500 (^GSPC)
YTD	-43.18%	-8.60%
1-Year	-63.19%	+6.00%
3-Year	+873.98%	+25.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viking Therapeutics Inc (1VT.MU)

Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ...

Viking Therapeutics, Inc. (VKTX): Among Takeover Rumors Hedge Funds Are Buying

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study

Viking Therapeutics to Report Q1 Earnings: What's in the Cards?

Viking Therapeutics (NasdaqCM:VKTX) Completes Enrollment For Phase 2 Trial Of VK2735

H.C. Wainwright still expects Viking to ‘differentiate’ after Lilly data

Eli Lilly jumps as results from weight-loss pill study rival competitor’s

JPMorgan says Lilly data ‘highly favorable’ for Structure Therapeutics

Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know

Eli Lilly Rockets 14% After Solidifying Its Lead For A Weight-Loss Pill

Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide

2 Stocks Down by 25% or More This Year to Buy and Hold

Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025

Pfizer Halts Obesity Pill Development Amid Safety Concerns

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill

Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback

Why Viking Therapeutics, Inc. (VKTX) Skyrocketed On Monday?

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Performance Overview